Novo Nordisk expands collaboration with US app company
Shortly after the US health company Amalgam received EU approval for its app for measuring how much insulin diabetes patients need to take per day, Novo Nordisk has expanded the collaboration between the two companies.
.jpg)
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company Novo Nordisk and US health firm Amalgam will collaborate to take over the European market for apps targeting type 2 diabetes sufferers.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
